Amblyopia is a neurodevelopmental abnormality that results in impaired visual acuity as well as stereopsis, and contrast sensitivity in one eye or in both due to physiological alterations in the visual pathways. Amblyopia could be clinically classified based on etiology as strabismic(misalignment of the eyes) amblyopia, anisometropic amblyopia (clinically significant difference of about 2 dioptre between the eyes) and mixed amblyopia (presence of both strabismus and anisometropia). Interocular Suppression plays a key role in visual deficit in Amblyopia. Amblyopic Suppression in relation to binocular vision refers to an inhibitory effect of the fellow eye over the amblyopic eye when both eyes are viewing. The characteristics of suppression in different types of amblyopia and the association of the suppression size and depth with the visual acuity loss and stereoacuity loss in amblyopia is not well understood. 

The currently available clinical tests for quantifying suppression are binary (presence or absence of suppression), rudimentary, and have limitations of test-retest reliability. While current amblyopia management focuses on visual acuity and stereoacuity improvements, changes in suppression are not systematically quantified. The interplay between visual acuity enhancement through amblyopia treatment and alterations in suppression size or depth remains inadequately explored. This advocates the need to develop a clinical tool to quantify suppression size and depth in clinical practice. Quantifying the suppression size and depth in amblyopia needs to be established in clinical practice and also it could provide insights into the changes in characteristics of suppression during amblyopia treatment. This could be further researched to get an effective monitoring of different management plans for amblyopia like patching, binocular therapies and anti-suppression therapy. 

Quantifying suppression size and depth would also provide a method to rank the amblyopes with nil stereo acuity. Thus a tool for the clinical quantification of suppression size and depth in amblyopia needs to be developed and validated. This research aims to fill this gap by developing a clinically viable tool for quantifying suppression size and depth in amblyopia. The proposed study seeks to establish the clinical utility of quantifying suppression characteristics, offering insights into dynamic changes during amblyopia treatment. This research could potentially pave the way for more effective monitoring and tailored management strategies for different amblyopic subtypes. Moreover, the exploration of suppression size and depth in association with visual acuity and stereoacuity loss in anisometropic amblyopia, specifically aniso-myopic and aniso-hypermetropic amblyopia, adds a novel dimension to this study.